ArticlePloS one2025
Evaluation of disparities in the incidence, presentation, and treatment of pediatric differentiated thyroid cancer in the United States (2000-2022).
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRates of pediatric differentiated thyroid cancer (DTC) have been increasing, yet disparities in incidence, diagnosis, and treatment across race and ethnicity have not been fully explored.
methodsWe assessed temporal trends in the incidence of pediatric DTC using data from 2000-2022 (excluding 2020 due to COVID-19) from the National Childhood Cancer Registry. Annual percent changes (APC) were calculated using joinpoint regression analysis overall and by race, ethnicity, age, and clinical factors. Differences in cancer presentation and treatment by race and ethnicity were evaluated using data from Surveillance, Epidemiology, and End Results (SEER) for 18 registries for 2006-2018, while accounting for socioeconomic status (SES).
resultsOverall pediatric DTC incidence increased 4.5% annually from 2000-2018 (95%CI: 3.8%-5.8%), then declined (-6.9%) through 2022 (95%CI: -14.5%, -1.2%). Rates of decline appeared sharpest among Non-Hispanic White patients. Incidence rates continued increasing among Non-Hispanic Asian/Pacific Islanders and patients diagnosed with tumors >4 cm. Compared to non-Hispanic White patients, non-Hispanic Black, non-Hispanic Asian/Pacific Islander, and Hispanic children were more likely to be diagnosed with a tumor >4 cm.
conclusionDeclines in reported pediatric thyroid cancer incidence, particularly among the smallest tumor sizes, after 2018 may be attributable to application of thyroid cancer management guidelines. However, the continued increase among those presenting with larger tumor sizes may support a true continued increase in incidence among some groups. The greater proportion of non-White children being diagnosed with larger tumors could be due to inequities related to timely access to care, differential application of thyroid management guidelines, differences in cancer subtypes, or other factors. These findings warrant further exploration when additional years of data are available.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.